Reports say the FDA's new voucher program is running behind on Lilly's pill

Regulators have delayed a decision on Eli Lilly's oral obesity drug orforglipron, along with three other drugs reviewed under the Food and Drug Administration's new Commissioner's National Priority Voucher pilot, according to trade press reports ^[1]. The new target action date for orforglipron is now April 10, 2026, later than an earlier date of March 28 that had been reported the previous month ^[1]. Lilly's original deadline under the program was May 20 ^[1].

The voucher program, launched in June 2025, was designed to shrink FDA review times from the usual 10 to 12 months down to just one or two months, in exchange for companies agreeing to national priorities such as addressing unmet medical needs and supporting domestic manufacturing ^[1]. Orforglipron and Boehringer Ingelheim's cancer drug zongertinib won vouchers in a second award cycle in November 2025, after Sanofi's Tzield and Disc Medicine's bitopertin received tickets in the program's first round in October ^[1].

The other delays reported alongside orforglipron involve different issues. Sanofi's Tzield, a therapy for type 1 diabetes, is being held up after regulators flagged safety signals including two seizures, one blood clotting episode, and one death, pushing its review back by more than a month ^[1]. A Sanofi spokesperson said no causal relationship to Tzield has been established and that blood clots and seizures have no known link to the drug based on the company's safety database ^[1]. Disc Medicine's bitopertin, for the rare blood disorder porphyria, faces a two-week delay over questions about its efficacy data and abuse risk ^[1]. Boehringer's zongertinib, a lung cancer drug, is now expected to get a decision in mid-February ^[1].

Speaking at the J.P. Morgan Healthcare Conference on January 13, Lilly CEO David Ricks said he now expects the FDA decision on orforglipron in the second quarter of 2026, calling the review a "rapid review" moving "at pace" ^[2]. Because the voucher program has never been authorized by Congress, there is no statutory deadline attached to it ^[2].

Why it matters for patients

For people waiting to know whether an oral GLP-1 pill from Lilly will reach pharmacies, the shifting dates mean more uncertainty about timing, not a change in whether the drug will eventually be reviewed. The delay comes as Novo Nordisk's oral Wegovy pill had just launched in the same week Ricks spoke, meaning Lilly's competing pill could reach the market later than once hoped ^[2]. A second-quarter decision would still let Lilly potentially begin selling orforglipron around the time Medicare's broader coverage of obesity medications is set to begin in April, according to the report ^[2]. Patients relying on injectable Zepbound or considering a future pill option should know that no approval has happened yet, and the reasons for delays vary by drug — the orforglipron slip has not been tied to any specific safety or efficacy concern in the sources reviewed, unlike the Sanofi and Disc Medicine cases ^[1].

What happens next

The reported target action date for orforglipron is now April 10, 2026, which falls within the second quarter Lilly's CEO referenced ^[1][2]. Boehringer's zongertinib decision is expected in mid-February 2026 ^[1]. Whether these dates hold, or slip again as they have already, is not yet known from the available reporting.